Revealing the changes in signaling pathways caused by tofacitinib in patients with rheumatoid arthritis through RNA sequencing and the correlation with clinical parameters

ConclusionsOur results highlighted the role of type I IFN, mainly including IFN α and IFN β, in the pathogenesis of RA and action for tofacitinib, and provided a new entry point for further elucidating the mechanism of morning stiffness.Key Points•Gene set IFN α and IFN β signaling was the most significantly down-regulated after tofacitinib treatment in RA patients.•Gene Oasl and Vgll3 were correlated with morning stiffness and significantly down-regulated due to the action of tofacitinib.•Type I IFN system was highlighted in the action of tofacitinib.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research